Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.67 |
| ▸ | CES1 | P23141 | 1/20 | 0.67 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.66 |
| ▸ | PARP1 | P09874 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 6/20 | 0.56 |
| ▸ | RAB9A | P51151 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL1894563 | 0.98 | CES2 (0.65) | CES2CES1ABCG2PARP1MAOB | |
| SCHEMBL31167605 | 0.87 | ABCG2 (0.78) | CES2CES1ABCG2PARP1MAOB | |
| SCHEMBL2961632 | 0.84 | CES2 (0.65) | CES2CES1ABCG2PARP1MAOB | |
| SCHEMBL14619169 | 0.84 | CES2 (0.65) | CES2CES1ABCG2PARP1MAOB | |
| SCHEMBL30267550 | 0.83 | ABCG2 (0.68) | CES2CES1ABCG2PARP1MAOB | |
| SCHEMBL8780343 | 0.82 | KMT2A (0.55) | CES2CES1ABCG2MAOBNPC1 | |
| SCHEMBL21843730 | 0.82 | ABCG2 (0.71) | CES2CES1ABCG2PARP1MAOB | |
| SCHEMBL30641502 | 0.82 | ABCG2 (0.71) | CES2CES1ABCG2PARP1MAOB | |
| SCHEMBL18674567 | 0.82 | CES2 (0.62) | CES2CES1ABCG2PARP1MAOB | |
| SCHEMBL8254893 | 0.82 | NPC1 (0.67) | CES2CES1ABCG2PARP1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4548097-A1 | IMMUNOASSAY USING CARBON NANOMATERIALS AND METHOD OF DETECTING TARGET ANTIGEN USING THE SAME | Lee, Ji Hoon (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119497822-A | Immunoassay method based on carbon nanomaterial and method for detecting target antigen by immunoassay method | 李知勋 | 2025-02-21 | — | — | CN | disclosed |
| WO-2024210572-A1 | NOVEL IMIDAZOLE DERIVATIVE AND USE THEREOF | 주식회사 펠레메드 | 2024-10-10 | — | — | WO | disclosed |
| US-12054472-B2 | 1,2,4-triazine-4-amine derivatives | NXERA PHARMA UK LIMITED (GB) | 2024-08-06 | — | — | US | disclosed |
| US-20240003891-A1 | IMMUNOASSAY USING CARBON NANOMATERIALS AND METHOD OF DETECTING TARGET ANTIGEN USING THE SAME | LEE JI HOON (US) | 2024-01-04 | — | — | US | disclosed |
| WO-2024006423-A1 | IMMUNOASSAY USING CARBON NANOMATERIALS AND METHOD OF DETECTING TARGET ANTIGEN USING THE SAME | LEE JI HOON (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230021177-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-10988455-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-27 | — | — | US | disclosed |
| CN-112638889-A | Urolithin A and derivatives thereof for use in therapy | 路易斯维尔大学研究基金会 | 2021-04-09 | — | — | CN | disclosed |
| US-20130324542-A1 | [1,2,4]TRIAZOLO[4,3-B][1,2,4]TRIAZINE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2013-12-05 | — | — | US | disclosed |
| EP-2650293-A1 | [1,2,4]TRIAZOLO[4,3-B][1,2,4]TRIAZINE COMPOUND, PREPARATION METHOD AND USE THEREOF | Shanghai Institute Materia Medica, Chinese Academy Of Sciences (CN) | 2013-10-16 | — | — | EP | disclosed |
| US-20130029963-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| EP-2531492-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | Heptares Therapeutics Limited (GB) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011095625-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LIMITED (GB) | 2011-08-11 | — | — | WO | disclosed |
| EP-0536896-B1 | Imidazolidyl macrolides having immunosuppressive activity | MERCK & CO INC (US) | 1997-12-17 | — | — | EP | disclosed |
| US-5344925-A | Autoimmune diseases; infections; organ transplants | MERCK & CO., INC. (US) | 1994-09-06 | — | — | US | disclosed |
| US-5247076-A | IMIDAZOLIDYL MACROLIDES HAVING IMMUNOSUPPRESSIVE ACTIVITY | MERCK & CO., INC. (US) | 1993-09-21 | — | — | US | disclosed |
| EP-0536896-A1 | Imidazolidyl macrolides having immunosuppressive activity | MERCK & CO. INC. (US) | 1993-04-14 | — | — | EP | disclosed |
| WO-1993005059-A1 | IMIDAZOLIDYL MACROLIDES | MERCK & CO., INC. (US) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988455-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2B, ADORA2A, ADORA1 | CES2 1956/4885CES1 680/4885ABCG2 827/4885 |
| US-20230021177-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | CES2 2166/4885CES1 793/4885ABCG2 695/4885 |
| US-12054472-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2A, ADORA2B, ADORA1 | CES2 1506/4885CES1 1376/4885ABCG2 314/4885 |
| US-20130324542-A1 | [1,2,4]TRIAZOLO[4,3-B][1,2,4]TRIAZINE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | MET, RET, ALK | CES2 672/4885CES1 522/4885ABCG2 215/4885 |
| US-20130029963-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | CES2 1956/4885CES1 680/4885ABCG2 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.